CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy

Authors :: Jayant Raikhelkar
Tamar S. Polonsky
Gene Kim
Michael R. Bishop
Gabriel Sayer
Anthony J. Kanelidis
Nir Uriel
Source :: JACC. CardioOncology, Vol 2, Iss 3, Pp 515-518 (2020), JACC: CardioOncology
Publication Year :: 2020
Publisher :: Elsevier, 2020.
Abstract: A 66-year-old woman with advanced diffuse large B-cell lymphoma (DLBCL) was referred for chimeric antigen receptor (CAR) T cell therapy. She was diagnosed with DLBCL 6 years prior to presentation and had no significant past medical history. She received a total of 10 cycles of rituximab

Subjects :: Oncology
medicine.medical_specialty
CAR, chimeric antigen receptor
lcsh:Diseases of the circulatory (Cardiovascular) system
Anthracycline
PAd, pulmonary artery diastolic pressure
medicine.medical_treatment
T cell
TTE, transthoracic echocardiogram
Cardiomyopathy
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
heart failure
lymphoma
anthracycline
HF, heart failure
lcsh:RC254-282
immune system diseases
hemic and lymphatic diseases
Internal medicine
LVEF, left ventricular ejection fraction
Medicine
Clinical Case Challenges
RHC, right heart catherization
business.industry
Immunotherapy
medicine.disease
CRS, cytokine release syndrome
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Chimeric antigen receptor
Lymphoma
medicine.anatomical_structure
lcsh:RC666-701
Heart failure
Rituximab
immunotherapy
Cardiology and Cardiovascular Medicine
business
DLBCL, diffuse large B-cell lymphoma
cardiomyopathy
GDMT, guideline-directed medical therapy
medicine.drug

Tools